ONE LEVEL DEEPER
AMGN
Warren Buffett frameworkThe Owner-OperatorBenjamin Graham frameworkThe Value ArchitectMichael Mauboussin frameworkThe Expectations EngineerHoward Marks frameworkThe Cycle WhispererPeter Lynch frameworkThe Everyday Edge

With 15.8x operating leverage yet only 1.43% implied growth, AMGN presents a textbook expectations gap.

cautiousBullishconviction

The market implies 1.43% perpetual growth for a business demonstrating 15.8x operating leverage and accelerating fundamentals — a rare expectations gap favoring the patient.

THE LENSES
THE EXPECTATIONS GAPexceptional

What expectations are embedded in the price, and are they reasonable?

Reverse DCF implies only 1.43% perpetual growth despite 10% trailing FCF growth
Stock trades 68.6% below DCF valuation in Q4'25
P/E at 33.09x sits at 88th percentile historically while earnings yield languishes at 15th percentile
Operating leverage coefficient of 15.8x means 1% revenue growth drives 15.8% operating income growth

The market has priced in dramatic deceleration that contradicts the business fundamentals. With demonstrated operating leverage of 15.8x and margins expanding from 15.5% to 39.8% over two years, the 1.43% implied growth represents an extreme disconnect between price and performance.

Expectations Gap: DCF vs Market
DCF FAIR VALUE
$1106
69% discount
MARKET PRICE
$348
Price implies 1.4% growth · Trailing: 10.0%
ROIC VS COST OF CAPITALtransitioning

Is the business creating or destroying value?

ROIC reached 4.98% in Q4'25, highest since Q1'22
WACC remains at 5.78%, creating negative 0.8% spread
ROIC sits at 98th percentile over 10 years despite negative spread
Company retired $6B in debt during 2025 while maintaining R&D growth

While the ROIC-WACC spread is technically negative, the trajectory is compelling — ROIC has reached decade highs and the gap is narrowing. The company's focus on debt reduction and organic investment over buybacks suggests management sees a path to positive value creation.

ROIC vs Cost of Capital
COMPETITIVE ADVANTAGE PERIODstrengthening

How long can the company earn returns above its cost of capital?

Operating margins expanded from 15.5% in Q4'23 to 39.8% in Q4'25
Revenue concentration HHI of 948 indicates diversified portfolio with no product exceeding 21% of sales
R&D spending increased 22% to $7.2B annually, including MariTide obesity drug development
Revenue correlates 0.88 with inflation, suggesting strong pricing power

The combination of margin expansion, portfolio diversification, and pricing power suggests a lengthening CAP. The 22% R&D increase while maintaining profitability indicates the company is investing to extend advantages rather than defending eroding positions.

Operating Margin
THE QUALITY OF GROWTHexceptional

Is growth creating or destroying value?

10% revenue growth drove 158% operating income growth via 15.8x operating leverage
FCF reached $8.1B despite 22% increase in R&D spending
Reinvestment rate shows R&D at 134% of Q4'25 operating cash flow
Gross margins remain stable while operating margins doubled

This is textbook value-creating growth — revenue expansion generates disproportionate profit growth through operating leverage while the company simultaneously invests heavily in future products. The ability to fund 22% R&D growth while expanding margins demonstrates exceptional capital efficiency.

Reinvestment: Capex vs OCF
KEY NUMBERS
VERDICT

Applying this framework reveals a business where operational excellence has outpaced market recognition by an extraordinary degree. The 1.43% growth implied by the stock price stands in stark contrast to demonstrated operating leverage of 15.8x and margin expansion from 15.5% to 39.8%. While the negative ROIC-WACC spread presents a concern, the trajectory and quality of growth suggest this gap will close. Does the market's conservative pricing reflect hidden pipeline risks, or has it simply failed to recognize a fundamental transformation?

This analysis applies Michael Mauboussin's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Michael Mauboussin. Educational purposes only. Not financial advice.

OTHER PERSPECTIVES
Warren Buffett framework
The Owner-Operator
Bullish
Howard Marks framework
The Cycle Whisperer
Bullish
Peter Lynch framework
The Everyday Edge
Leaning Bullish
Benjamin Graham framework
The Value Architect
Leaning Bullish
Explore
Strategy IncMSTRLinde plcLINGE HealthCare Technologies Inc.GEHCFastenal CompanyFASTCisco Systems, Inc.CSCOConstellation Energy CorporationCEG
EDUCATIONAL ONLY · NOT FINANCIAL ADVICEv2